<unk>  (INN; trade name Prevymis) is an antiviral drug for the treatment of cytomegalovirus (CMV) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections. The drug was developed by Merck & Co. The drug was granted fast track status by the US Food and Drug Administration (FDA) and orphan drug status by the European Medicines Agency. It is now approved for prevention of CMV infection and disease in recipients of an allogeneic stem cell transplant. The FDA considers it to be a first-in-class medication.
Letermovir
Saquinavir
Entecavir
Fostemsavir
Coronavir
Lamivudine
Fosamprenavir
Abacavir